

# Predrag Sikiric

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6200917/publications.pdf>

Version: 2024-02-01

196  
papers

4,578  
citations

76196

40  
h-index

182168

51  
g-index

197  
all docs

197  
docs citations

197  
times ranked

624  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pentadecapeptide BPC 157 and the central nervous system. <i>Neural Regeneration Research</i> , 2022, 17, 482.	1.6	17
2	Gastric pentadecapeptide BPC 157 in cytoprotection to resolve major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome. <i>World Journal of Gastroenterology</i> , 2022, 28, 23-46.	1.4	14
3	Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats. <i>Biomedicines</i> , 2022, 10, 265.	1.4	13
4	Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma. <i>Biomedicines</i> , 2022, 10, 89.	1.4	13
5	Novel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy. <i>Current Issues in Molecular Biology</i> , 2022, 44, 1901-1927.	1.0	9
6	Do We Have a New Psoriasis Drug?. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
7	Therapy Effect of the Stable Gastric Pentadecapeptide BPC 157 on Acute Pancreatitis as Vascular Failure-Induced Severe Peripheral and Central Syndrome in Rats. <i>Biomedicines</i> , 2022, 10, 1299.	1.4	11
8	BPC 157, L-NAME, L-Arginine, NO-Relation, in the Suited Rat Ketamine Models Resembling "Negative-Like" Symptoms of Schizophrenia. <i>Biomedicines</i> , 2022, 10, 1462.	1.4	4
9	Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling "positive-like"™ symptoms of schizophrenia. <i>Behavioural Brain Research</i> , 2021, 396, 112919.	1.2	11
10	Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension. <i>Biomedicines</i> , 2021, 9, 609.	1.4	20
11	BPC 157 as a Therapy for Retinal Ischemia Induced by Retrobulbar Application of L-NAME in Rats. <i>Frontiers in Pharmacology</i> , 2021, 12, 632295.	1.6	11
12	Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. <i>Frontiers in Pharmacology</i> , 2021, 12, 627533.	1.6	24
13	BPC 157 Therapy and the Permanent Occlusion of the Superior Sagittal Sinus in Rat: Vascular Recruitment. <i>Biomedicines</i> , 2021, 9, 744.	1.4	23
14	Occluded Superior Mesenteric Artery and Vein. Therapy with the Stable Gastric Pentadecapeptide BPC 157. <i>Biomedicines</i> , 2021, 9, 792.	1.4	19
15	Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal. <i>Biomedicines</i> , 2021, 9, 822.	1.4	13
16	Complex Syndrome of the Complete Occlusion of the End of the Superior Mesenteric Vein, Opposed with the Stable Gastric Pentadecapeptide BPC 157 in Rats. <i>Biomedicines</i> , 2021, 9, 1029.	1.4	20
17	Physiological and Immunological Status of Adult Honeybees ( <i>Apis mellifera</i> ) Fed Sugar Syrup Supplemented with Pentadecapeptide BPC 157. <i>Biology</i> , 2021, 10, 891.	1.3	13
18	Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats. <i>Biomedicines</i> , 2021, 9, 1206.	1.4	4

#	ARTICLE	IF	CITATIONS
19	Robert's Intra-gastric Alcohol-Induced Gastric Lesion Model as an Escalated General Peripheral and Central Syndrome, Counteracted by the Stable Gastric Pentadecapeptide BPC 157. <i>Biomedicines</i> , 2021, 9, 1300.	1.4	18
20	Over-Dose Lithium Toxicity as an Occlusive-like Syndrome in Rats and Gastric Pentadecapeptide BPC 157. <i>Biomedicines</i> , 2021, 9, 1506.	1.4	18
21	Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats. <i>Frontiers in Pharmacology</i> , 2021, 12, 718147.	1.6	15
22	Novel insight into Robert's cytoprotection: complex therapeutic effect of cytoprotective pentadecapeptide BPC 157 in rats with perforated stomach throughout modulation of nitric oxide-system. Comparison with L-arginine, ranitidine and pantoprazole therapy and L-N-nitro-L-arginine methyl ester worsening. <i>Journal of Physiology and Pharmacology</i> , 2021, 72, .	1.1	4
23	In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro. <i>Emergency Medicine International</i> , 2020, 2020, 1-20.	0.3	17
24	Physiological and Pharmacological Mechanisms in Gastrointestinal Protection, Ulcer Healing and Mucosal Repair - An Update. <i>Current Pharmaceutical Design</i> , 2020, 26, 2933-2935.	0.9	2
25	The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats. <i>Brain and Behavior</i> , 2020, 10, e01726.	1.0	38
26	Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy. <i>Current Pharmaceutical Design</i> , 2020, 26, 2991-3000.	0.9	17
27	BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection. <i>Current Pharmaceutical Design</i> , 2020, 26, 2971-2981.	0.9	34
28	Pentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion. <i>World Journal of Hepatology</i> , 2020, 12, 12-196.	0.8	32
29	Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2020, 11, 1-19.	0.5	31
30	Bowel adhesion and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine in rats. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2020, 11, 93-109.	0.6	11
31	Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. <i>Gut and Liver</i> , 2020, 14, 153-167.	1.4	35
32	Pentadecapeptide BPC 157 Shortens Duration of Tetracaine- and Oxybuprocaine-Induced Corneal Anesthesia in Rats. <i>Acta Clinica Croatica</i> , 2020, 59, 394-406.	0.1	2
33	Therapy of the rat hemorrhagic cystitis induced by cyclophosphamide. Stable gastric pentadecapeptide BPC 157, L-arginine, L-NAME. <i>European Journal of Pharmacology</i> , 2019, 861, 172593.	1.7	36
34	Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. <i>Journal of Orthopaedic Surgery and Research</i> , 2019, 14, 199.	0.9	18
35	Stable gastric pentadecapeptide BPC 157 in the therapy of the rats with bile duct ligation. <i>European Journal of Pharmacology</i> , 2019, 847, 130-142.	1.7	37
36	Intra-gastric Application of Aspirin, Clopidogrel, Cilostazol, and BPC 157 in Rats: Platelet Aggregation and Blood Clot. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-9.	1.9	30

#	ARTICLE	IF	CITATIONS
37	Stable Gastric Pentadecapeptide BPC 157 Antagonized Local Anesthetic Effect of Lidocaine. FASEB Journal, 2019, 33, 822.1.	0.2	0
38	Stable Gastric Pentadecapeptide BPC 157 in Rats Subjected to High Fructose (80%) Diet for One Month Counteracts Hypertension and Compromised Optic Disc Head Circulation and Following Atrophy. FASEB Journal, 2019, 33, .	0.2	0
39	Stable Gastric Pentadecapeptide BPC 157 in Rats Subjected to High Salt (30%) Diet for One Month Counteracts Hypertension and Compromised Optic Disc Head Circulation and Following Atrophy. FASEB Journal, 2019, 33, 822.8.	0.2	0
40	Bypassing Major Venous Occlusion and Duodenal Lesions in Rats, and Therapy with the Stable Gastric Pentadecapeptide BPC 157, L-NAME and L-arginine. FASEB Journal, 2019, 33, 822.2.	0.2	0
41	Stable Gastric Pentadecapeptide BPC 157 in Rats with Episcleral Veins Cauterization, Glaucoma Model, Preserved Retinal and Optic Nerve Integrity. FASEB Journal, 2019, 33, 822.6.	0.2	0
42	Pentadecapeptide BPC 157 Counteracts the Adverse Effect of Lithium Overdose in Rats. FASEB Journal, 2019, 33, 822.4.	0.2	1
43	Stable Gastric Pentadecapeptide BPC 157 Counteracts Convulsions Induced by Concomitant Application of Atypical Neuroleptic, SSRI and NSAID, Risperidone, Citalopram and Metamizole in Rats. FASEB Journal, 2019, 33, 822.7.	0.2	0
44	Stable Gastric Pentadecapeptide BPC 157 Recovers Motor Function After Rat Spinal Cord Injury. FASEB Journal, 2019, 33, 822.5.	0.2	0
45	Spinal Instability in Rats Counteracted by Pentadecapeptide BPC 157. FASEB Journal, 2019, 33, 822.3.	0.2	0
46	Rat inferior caval vein (ICV) ligation and particular new insights with the stable gastric pentadecapeptide BPC 157. Vascular Pharmacology, 2018, 106, 54-66.	1.0	49
47	Stable gastric pentadecapeptide BPC 157 in honeybee ( <i>Apis mellifera</i> ) therapy, to control <i>Nosema ceranae</i> invasions in apiary conditions. Journal of Veterinary Pharmacology and Therapeutics, 2018, 41, 614-621.	0.6	25
48	New Mechanisms of GI Ulceration & Healing: Physiology, Pharmacology & Pathology. Current Pharmaceutical Design, 2018, 24, 1913-1915.	0.9	0
49	Engineering recombinant <i>Lactococcus lactis</i> as a delivery vehicle for BPC-157 peptide with antioxidant activities. Applied Microbiology and Biotechnology, 2018, 102, 10103-10117.	1.7	16
50	Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing. Current Pharmaceutical Design, 2018, 24, 1990-2001.	0.9	48
51	BPC157 as Potential Agent Rescuing from Cancer Cachexia. Current Pharmaceutical Design, 2018, 24, 1947-1956.	0.9	47
52	BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current Pharmaceutical Design, 2018, 24, 1972-1989.	0.9	52
53	An endogenous defensive concept, renewed cytoprotection/adaptive cytoprotection: intra(per)-oral/intragastric strong alcohol in rat. Involvement of pentadecapeptide BPC 157 and nitric oxide system. Journal of Physiology and Pharmacology, 2018, 69, .	1.1	10
54	Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine. World Journal of Gastroenterology, 2018, 24, 5366-5378.	1.4	34

#	ARTICLE	IF	CITATIONS
55	Counteraction of perforated cecum lesions in rats: effects of pentadecapeptide BPC 157, L-NAME and L-arginine. <i>World Journal of Gastroenterology</i> , 2018, 24, 5462-5476.	1.4	34
56	BPC 157 Rescues NO-system in Perforated Stomach and Caecum. <i>FASEB Journal</i> , 2018, 32, 832.12.	0.2	0
57	Caustic Lesions of Esophagus in Rats and Therapy with Stable Gastric Pentadecapeptide BPC 157. <i>FASEB Journal</i> , 2018, 32, 832.16.	0.2	0
58	Stable Pentadecapeptide BPC 157 and Vesicovaginal Fistulas in Rats. <i>FASEB Journal</i> , 2018, 32, 832.15.	0.2	0
59	Bypassing Occlusion: Abdominal Aorta Occlusion in Rats and the Therapy with the Stable Gastric Pentadecapeptide BPC 157. <i>FASEB Journal</i> , 2018, 32, 699.13.	0.2	0
60	BPC 157 Therapy Heals Tendon Muscle Junction in Rats. <i>FASEB Journal</i> , 2018, 32, 832.13.	0.2	0
61	The Effect of BPC 157 on Tracheocutaneous Fistula Healing in Rat. <i>FASEB Journal</i> , 2018, 32, 832.14.	0.2	0
62	Hypermagnesemia disturbances in rats, NO-related: pentadecapeptide BPC 157 abrogates, L-NAME and L-arginine worsen. <i>Inflammopharmacology</i> , 2017, 25, 439-449.	1.9	22
63	Cyclophosphamide induced stomach and duodenal lesions as a NO-system disturbance in rats: L-NAME, L-arginine, stable gastric pentadecapeptide BPC 157. <i>Inflammopharmacology</i> , 2017, 25, 255-264.	1.9	41
64	Class side effects: decreased pressure in the lower oesophageal and the pyloric sphincters after the administration of dopamine antagonists, neuroleptics, anti-emetics, L-NAME, pentadecapeptide BPC 157 and L-arginine. <i>Inflammopharmacology</i> , 2017, 25, 511-522.	1.9	38
65	BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulphiride, and metoclopramide in rats. <i>Life Sciences</i> , 2017, 186, 66-79.	2.0	33
66	Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME. <i>World Journal of Gastroenterology</i> , 2017, 23, 5304.	1.4	44
67	Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights. <i>World Journal of Gastroenterology</i> , 2017, 23, 8465-8488.	1.4	49
68	Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution?. <i>Current Pharmaceutical Design</i> , 2017, 23, 4012-4028.	0.9	39
69	Nonsteroidal anti-inflammatory drugs-induced failure of lower esophageal and pyloric sphincter and counteraction of sphincters failure with stable gastric pentadecapeptide BPC 157 in rats. <i>Journal of Physiology and Pharmacology</i> , 2017, 68, 265-272.	1.1	7
70	EDITORIAL (Thematic Issue: Brain Gut Axis-New View). <i>Current Neuropharmacology</i> , 2016, 14, 840-841.	1.4	1
71	Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. <i>Current Neuropharmacology</i> , 2016, 14, 857-865.	1.4	55
72	Effects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short-Bowel Rats. <i>PLoS ONE</i> , 2016, 11, e0162590.	1.1	43

#	ARTICLE	IF	CITATIONS
73	BPC 157: The counteraction of succinylcholine, hyperkalemia, and arrhythmias. <i>European Journal of Pharmacology</i> , 2016, 781, 83-91.	1.7	26
74	Stable gastric pentadecapeptide BPC 157 and bupivacaine. <i>European Journal of Pharmacology</i> , 2016, 793, 56-65.	1.7	29
75	NO system dependence of atropine-induced mydriasis and L-NAME- and L-arginine-induced miosis: Reversal by the pentadecapeptide BPC 157 in rats and guinea pigs. <i>European Journal of Pharmacology</i> , 2016, 771, 211-219.	1.7	26
76	Stable gastric pentadecapeptide BPC 157 heals rat colovesical fistula. <i>European Journal of Pharmacology</i> , 2016, 780, 1-7.	1.7	12
77	Stable gastric pentadecapeptide BPC 157 heals rectovaginal fistula in rats. <i>Life Sciences</i> , 2016, 148, 63-70.	2.0	12
78	Esophagogastric anastomosis in rats: Improved healing by BPC 157 and L-arginine, aggravated by L-NAME. <i>World Journal of Gastroenterology</i> , 2016, 22, 9127.	1.4	17
79	Pentadecapeptide BPC 157 Reduces Bleeding and Thrombocytopenia after Amputation in Rats Treated with Heparin, Warfarin, L-NAME and L-Arginine. <i>PLoS ONE</i> , 2015, 10, e0123454.	1.1	49
80	Perforating corneal injury in rat and pentadecapeptide BPC 157. <i>Experimental Eye Research</i> , 2015, 136, 9-15.	1.2	16
81	BPC 157 antagonized the general anaesthetic potency of thiopental and reduced prolongation of anaesthesia induced by L-NAME/thiopental combination. <i>Inflammopharmacology</i> , 2015, 23, 329-336.	1.9	10
82	Perforating Corneal Injury in Rat and Pentadecapeptide BPC 157. <i>FASEB Journal</i> , 2015, 29, 1024.1.	0.2	0
83	BPC 157 Counteracts Convulsions after Continuous Haloperidol Overdose Administration in Rats. <i>FASEB Journal</i> , 2015, 29, 771.13.	0.2	0
84	The Effect of Pentadecapeptide BPC 157 on System Circulation and Thrombogenesis after Ligation of Vena Cava Inferior. <i>FASEB Journal</i> , 2015, 29, 941.6.	0.2	0
85	Spinal Cord Injury in Rat – Therapeutic Effect of Pentadecapeptide BPC 157. <i>FASEB Journal</i> , 2015, 29, 617.5.	0.2	1
86	Atropine-induced mydriasis NO-system dependent, L-NAME-induced miosis, L-arginine-induced miosis, and counteraction by stable gastric pentadecapeptide BPC 157, in living rats. <i>FASEB Journal</i> , 2015, 29, 1024.6.	0.2	0
87	BPC 157 Counteracts Gastric Lesions after Bilateral Nephrectomy and Attenuates Deleterious Course in Rats. <i>FASEB Journal</i> , 2015, 29, 628.10.	0.2	4
88	Duodenocutaneous fistula in rats as a model for "wound healing-therapy" in ulcer healing: the effect of pentadecapeptide BPC 157, L-nitro-arginine methyl ester and L-arginine. <i>Journal of Physiology and Pharmacology</i> , 2015, 66, 581-90.	1.1	12
89	BPC 157 and Blood Vessels. <i>Current Pharmaceutical Design</i> , 2014, 20, 1121-1125.	0.9	46
90	Editorial (Thematic Issue: From Gut Inflammation to Gastrointestinal Disorders Current Update on) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i> <i>Pharmaceutical Design</i> , 2014, 20, 1039-1040.	0.9	1

#	ARTICLE	IF	CITATIONS
91	Pentadecapeptide BPC 157 and anaphylactoid reaction in rats and mice after intravenous dextran and white egg administration. <i>European Journal of Pharmacology</i> , 2014, 727, 75-79.	1.7	6
92	Stable Gastric Pentadecapeptide BPC 157-NO-system Relation. <i>Current Pharmaceutical Design</i> , 2014, 20, 1126-1135.	0.9	76
93	Pentadecapeptide BPC 157 counteracts heterotopic ossification in rats (844.10). <i>FASEB Journal</i> , 2014, 28, 844.10.	0.2	0
94	BPC 157 antagonized the general anesthetic potency of thiopental and reduced prolongation of anesthesia time induced by L-NAME/thiopental combination (1061.3). <i>FASEB Journal</i> , 2014, 28, 1061.3.	0.2	0
95	Pentadecapeptide BPC 157 and anaphylactoid reaction in rats and mice after intravenous dextran and white egg administration (1056.7). <i>FASEB Journal</i> , 2014, 28, 1056.7.	0.2	0
96	The effect of pentadecapeptide BPC 157 in metamphetamine-induced dopaminergic neurotoxicity (1143.11). <i>FASEB Journal</i> , 2014, 28, 1143.11.	0.2	0
97	Effect of pentadecapeptide BPC 157 on rotator cuff tear injury in rat (844.9). <i>FASEB Journal</i> , 2014, 28, 844.9.	0.2	0
98	Pentadecapeptide BPC 157 given intraarticular counteracts knee osteoarthritis in rats (844.11). <i>FASEB Journal</i> , 2014, 28, 844.11.	0.2	0
99	Pentadecapeptide BPC 157 counteracts celecoxib-induced lesions on gastric mucosa in rats (840.6). <i>FASEB Journal</i> , 2014, 28, 840.6.	0.2	0
100	Mortal hyperkalemia disturbances in rats are NO-system related. The life saving effect of pentadecapeptide BPC 157. <i>Regulatory Peptides</i> , 2013, 181, 50-66.	1.9	47
101	Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy. <i>European Journal of Pharmacology</i> , 2013, 701, 203-212.	1.7	43
102	Monitoring the healing process of rat bones using Raman spectroscopy. <i>Journal of Molecular Structure</i> , 2013, 1044, 308-313.	1.8	11
103	Salutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incontinence models in female rats. <i>Medical Science Monitor Basic Research</i> , 2013, 19, 93-102.	2.6	15
104	Stable anti-ulcer gastric pentadecapeptide BPC 157 also for multiple sclerosis: Counteraction of cuprizone brain injuries and motor disability. <i>FASEB Journal</i> , 2013, 27, 662.9.	0.2	0
105	Pentadecapeptide BPC 157 after 70% liver resection in rats. <i>FASEB Journal</i> , 2013, 27, 1093.26.	0.2	0
106	Pentadecapeptide BPC 157 and rat osteoarthritis. <i>FASEB Journal</i> , 2013, 27, 888.9.	0.2	0
107	Stable gastric pentadecapeptide BPC 157 for colitis and multiple sclerosis: Healing of cysteamine-colitis and colon-colon-anastomosis. <i>FASEB Journal</i> , 2013, 27, 1093.18.	0.2	0
108	Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. <i>Journal of Physiology and Pharmacology</i> , 2013, 64, 597-612.	1.1	41

#	ARTICLE	IF	CITATIONS
109	Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157. <i>Current Medicinal Chemistry</i> , 2012, 19, 126-132.	1.2	49
110	Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin or aspirin. <i>Thrombosis Research</i> , 2012, 129, 652-659.	0.8	49
111	Toxicity by NSAIDs. Counteraction by Stable Gastric Pentadecapeptide BPC 157. <i>Current Pharmaceutical Design</i> , 2012, 19, 76-83.	0.9	9
112	Toxicity by NSAIDs. Counteraction by Stable Gastric Pentadecapeptide BPC 157. <i>Current Pharmaceutical Design</i> , 2012, 19, 76-83.	0.9	58
113	Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: Diclofenac-induced gastrointestinal, liver, and encephalopathy lesions. <i>Life Sciences</i> , 2011, 88, 535-542.	2.0	62
114	Editorial [Hot Topic: Emerging Drugs in Gastrointestinal Tract (Executive Guest Editor: Predrag Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 54	0.9	0
115	Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. <i>Current Pharmaceutical Design</i> , 2011, 17, 1612-1632.	0.9	61
116	Ibuprofen hepatic encephalopathy, hepatomegaly, gastric lesion and gastric pentadecapeptide BPC 157 in rats. <i>European Journal of Pharmacology</i> , 2011, 667, 322-329.	1.7	49
117	BPC 157 therapy to detriment sphincters failure-esophagitis-pancreatitis in rat and acute pancreatitis patients low sphincters pressure. <i>Journal of Physiology and Pharmacology</i> , 2011, 62, 527-34.	1.1	10
118	Revised Roberts Cytoprotection and Adaptive Cytoprotection and Stable Gastric Pentadecapeptide BPC 157. Possible Significance and Implications for Novel Mediator. <i>Current Pharmaceutical Design</i> , 2010, 16, 1224-1234.	0.9	63
119	Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. <i>Journal of Orthopaedic Research</i> , 2010, 28, 1155-1161.	1.2	25
120	Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. <i>Regulatory Peptides</i> , 2010, 160, 33-41.	1.9	32
121	Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. <i>Regulatory Peptides</i> , 2010, 160, 26-32.	1.9	30
122	Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. <i>Medical Science Monitor</i> , 2010, 16, BR81-88.	0.5	15
123	High hepatotoxic dose of paracetamol produces generalized convulsions and brain damage in rats. A counteraction with the stable gastric pentadecapeptide BPC 157 (PL 14736). <i>Journal of Physiology and Pharmacology</i> , 2010, 61, 241-50.	1.1	45
124	Therapy for Unhealed Gastrocutaneous Fistulas in Rats as a Model for Analogous Healing of Persistent Skin Wounds and Persistent Gastric Ulcers: Stable Gastric Pentadecapeptide BPC 157, Atropine, Ranitidine, and Omeprazole. <i>Digestive Diseases and Sciences</i> , 2009, 54, 46-56.	1.1	24
125	Gastric Pentadecapeptide BPC 157 and Short Bowel Syndrome in Rats. <i>Digestive Diseases and Sciences</i> , 2009, 54, 2070-2083.	1.1	29
126	Inhibition of methyl digoxin-induced arrhythmias by pentadecapeptide BPC 157: A relation with NO-system. <i>Regulatory Peptides</i> , 2009, 156, 83-89.	1.9	52



#	ARTICLE	IF	CITATIONS
127	M1712 High Hepatotoxic Overdose of Paracetamol Produces Generalized Convulsions and Brain Damage in Rats. a Counteraction with the Stable Gastric Pentadecapeptide BPC 157 (PL 14736). <i>Gastroenterology</i> , 2009, 136, A-416.	0.6	3
128	Over-dose insulin and stable gastric pentadecapeptide BPC 157. Attenuated gastric ulcers, seizures, brain lesions, hepatomegaly, fatty liver, breakdown of liver glycogen, profound hypoglycemia and calcification in rats. <i>Journal of Physiology and Pharmacology</i> , 2009, 60 Suppl 7, 107-14.	1.1	24
129	Antiinflammatory effect of BPC 157 on experimental periodontitis in rats. <i>Journal of Physiology and Pharmacology</i> , 2009, 60 Suppl 7, 115-22.	1.1	15
130	Abdominal aorta anastomosis in rats and stable gastric pentadecapeptide BPC 157, prophylaxis and therapy. <i>Journal of Physiology and Pharmacology</i> , 2009, 60 Suppl 7, 161-5.	1.1	22
131	Gastric pentadecapeptide BPC 157 counteracts morphine-induced analgesia in mice. <i>Journal of Physiology and Pharmacology</i> , 2009, 60 Suppl 7, 177-81.	1.1	6
132	Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. <i>Journal of Physiology and Pharmacology</i> , 2009, 60 Suppl 7, 191-6.	1.1	17
133	Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone. <i>Inflammation Research</i> , 2008, 57, 205-210.	1.6	28
134	Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. <i>Surgery Today</i> , 2008, 38, 716-725.	0.7	38
135	Pentadecapeptide BPC 157, in Clinical Trials as a Therapy for Inflammatory Bowel Disease (PL14736), Is Effective in the Healing of Colocutaneous Fistulas in Rats: Role of the Nitric Oxide-System. <i>Journal of Pharmacological Sciences</i> , 2008, 108, 7-17.	1.1	40
136	Prolonged Esophagitis After Primary Dysfunction of the Pyloric Sphincter in the Rat and Therapeutic Potential of the Gastric Pentadecapeptide BPC 157. <i>Journal of Pharmacological Sciences</i> , 2007, 104, 7-18.	1.1	23
137	Stable Gastric Pentadecapeptide BPC 157 in Trials for Inflammatory Bowel Disease (PL-10, PLD-116,) Tj ETQq1 1 0.784314 rgBT /Over	0.7	33
138	An Experimental Model of Prolonged Esophagitis With Sphincter Failure in the Rat and the Therapeutic Potential of Gastric Pentadecapeptide BPC 157. <i>Journal of Pharmacological Sciences</i> , 2006, 102, 269-277.	1.1	23
139	Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL) Tj ETQq1 1 0.784314 rgBT /Over	1.9	43
140	Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. <i>Journal of Orthopaedic Research</i> , 2006, 24, 1109-1117.	1.2	45
141	Achilles Detachment in Rat and Stable Gastric Pentadecapeptide BPC 157: Promoted Tendon-to-Bone Healing and Opposed Corticosteroid Aggravation. <i>Journal of Orthopaedic Research</i> , 2006, 24, 982-989.	1.2	37
142	The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. The effect of N(G)-nitro-L-arginine methyl ester and L-arginine. <i>Medical Science Monitor</i> , 2006, 12, BR36-45.	0.5	11
143	The presentation and organization of adaptive cytoprotection in the rat stomach, duodenum, and colon. Dedicated to AndrÁ© Robert the founder of the concept of cytoprotection and adaptive cytoprotection. <i>Medical Science Monitor</i> , 2006, 12, BR146-53.	0.5	7
144	Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. <i>European Journal of Pharmacology</i> , 2005, 512, 173-179.	1.7	27

#	ARTICLE	IF	CITATIONS
145	The stable gastric pentadecapeptide BPC 157, given locally, improves CO2 laser healing in mice. <i>Burns</i> , 2005, 31, 310-315.	1.1	25
146	Gastric pentadecapeptide BPC 157 promotes corneal epithelial defects healing in rats. <i>Collegium Antropologicum</i> , 2005, 29, 321-5.	0.1	13
147	The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. <i>European Journal of Pharmacology</i> , 2004, 499, 285-290.	1.7	22
148	Effects of Pentadecapeptide BPC157 on Regional Serotonin Synthesis in the Rat Brain: $\pm$ -Methyl-L-Tryptophan Autoradiographic Measurements. <i>Life Sciences</i> , 2004, 76, 345-357.	2.0	31
149	BPC 157 inhibits cell growth and VEGF signalling via the MAPK kinase pathway in the human melanoma cell line. <i>Melanoma Research</i> , 2004, 14, A14-A15.	0.6	14
150	Doxorubicine-Congestive Heart Failure-Increased Big Endothelin-1 Plasma Concentration: Reversal by Amlodipine, Losartan, and Gastric Pentadecapeptide BPC157 in Rat and Mouse. <i>Journal of Pharmacological Sciences</i> , 2004, 95, 19-26.	1.1	74
151	Different effect of antiulcer agents on rat cysteamine-induced duodenal ulcer after sialoadenectomy, but not gastrectomy. <i>European Journal of Pharmacology</i> , 2003, 477, 73-80.	1.7	15
152	Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. <i>Journal of Orthopaedic Research</i> , 2003, 21, 976-983.	1.2	46
153	Corticosteroid-impairment of healing and gastric pentadecapeptide BPC-157 creams in burned mice. <i>Burns</i> , 2003, 29, 323-334.	1.1	47
154	Comment on "Use of recombinant human bone morphogenetic protein-2 to enhance tendon healing in a bone tunnel". <i>American Journal of Sports Medicine</i> , 2003, 31, 636-7; author reply 637-8.	1.9	7
155	Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances. <i>Acta Pharmacologica Sinica</i> , 2002, 23, 412-22.	2.8	15
156	Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. <i>Burns</i> , 2001, 27, 817-827.	1.1	64
157	Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice. <i>Life Sciences</i> , 2001, 68, 1905-1912.	2.0	21
158	Cysteamine-colon and cysteamine-duodenum lesions in rats. Attenuation by gastric pentadecapeptide BPC 157, cimetidine, ranitidine, atropine, omeprazole, sulphasalazine and methylprednisolone. <i>Journal of Physiology (Paris)</i> , 2001, 95, 261-270.	2.1	17
159	Therapy effect of antiulcer agents on new chronic cysteamine colon lesion in rat. <i>Journal of Physiology (Paris)</i> , 2001, 95, 283-288.	2.1	17
160	Ethanol gastric lesion aggravated by lung injury in rat. Therapy effect of antiulcer agents. <i>Journal of Physiology (Paris)</i> , 2001, 95, 289-293.	2.1	10
161	Chronic cytoprotection: pentadecapeptide BPC 157, ranitidine and propranolol prevent, attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats.. <i>Journal of Physiology (Paris)</i> , 2001, 95, 295-301.	2.1	21
162	Lung lesions and anti-ulcer agents beneficial effect: Anti-ulcer agents pentadecapeptide BPC 157, ranitidine, omeprazole and atropine ameliorate lung lesion in rats. <i>Journal of Physiology (Paris)</i> , 2001, 95, 303-308.	2.1	18

#	ARTICLE	IF	CITATIONS
163	Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine. <i>Journal of Physiology (Paris)</i> , 2001, 95, 315-324.	2.1	34
164	Anxiolytic effect of BPC-157, a gastric pentadecapeptide: shock probe/burying test and light/dark test. <i>Acta Pharmacologica Sinica</i> , 2001, 22, 225-30.	2.8	12
165	Gastric mucosal lesions induced by complete dopamine system failure in rats. The effects of dopamine agents, ranitidine, atropine, omeprazole and pentadecapeptide BPC 157. <i>Journal of Physiology (Paris)</i> , 2000, 94, 105-110.	2.1	21
166	The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt's test and chronic unpredictable stress in rats. A comparison with antidepressants. <i>Journal of Physiology (Paris)</i> , 2000, 94, 99-104.	2.1	25
167	The pharmacological properties of the novel peptide BPC 157 (PL-10). <i>Inflammopharmacology</i> , 1999, 7, 1-14.	1.9	14
168	New model of cytoprotection/adaptive cytoprotection in rats: endogenous small irritants, antiulcer agents and indomethacin. <i>European Journal of Pharmacology</i> , 1999, 364, 23-31.	1.7	28
169	Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats. <i>European Journal of Pharmacology</i> , 1999, 379, 19-31.	1.7	46
170	A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <i>Journal of Physiology (Paris)</i> , 1999, 93, 505-512.	2.1	37
171	The effect of pentadecapeptide BPC 157, H <sub>2</sub> -blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation. <i>Journal of Physiology (Paris)</i> , 1999, 93, 479-485.	2.1	41
172	Long-lasting cytoprotection after pentadecapeptide BPC 157, ranitidine, sucralfate or cholestyramine application in reflux oesophagitis in rats. <i>Journal of Physiology (Paris)</i> , 1999, 93, 467-477.	2.1	18
173	Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation. <i>Bone</i> , 1999, 24, 195-202.	1.4	49
174	The effect of a novel pentadecapeptide BPC 157 on development of tolerance and physical dependence following repeated administration of diazepam. <i>Chinese Journal of Physiology</i> , 1999, 42, 171-9.	0.4	6
175	A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine. <i>Biological Psychiatry</i> , 1998, 43, 511-519.	0.7	40
176	Lesions induced in colon and duodenum by cysteamine: Salutory effect of pentadecapeptide BPC 157 and other antiulcer agents. <i>Gastroenterology</i> , 1998, 114, A1085.	0.6	1
177	The influence of a novel pentadecapeptide, BPC 157, on NG-nitro-l-arginine methylester and l-arginine effects on stomach mucosa integrity and blood pressure. <i>European Journal of Pharmacology</i> , 1997, 332, 23-33.	1.7	116
178	Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. <i>Journal of Physiology (Paris)</i> , 1997, 91, 113-122.	2.1	46
179	The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks. <i>Journal of Physiology (Paris)</i> , 1997, 91, 139-149.	2.1	65
180	BPC 157's effect on healing. <i>Journal of Physiology (Paris)</i> , 1997, 91, 173-178.	2.1	42

#	ARTICLE	IF	CITATIONS
181	Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress. <i>Digestive Diseases and Sciences</i> , 1997, 42, 661-671.	1.1	11
182	Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectomized rats: a model for cytoprotective studies. <i>Digestive Diseases and Sciences</i> , 1997, 42, 1029-1037.	1.1	43
183	Pentadecapeptide BPC 157 Beneficially Influences the Healing of Colonâ€™Colon Anastomoses in Rats. , 1997, , 249-258.		5
184	Beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin, and capsaicin neurotoxicity. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1604-1614.	1.1	56
185	Salutary and prophylactic effect of pentadecapeptide BPC 157 on acute pancreatitis and concomitant gastroduodenal lesions in rats. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1518-1526.	1.1	30
186	The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides. <i>Life Sciences</i> , 1994, 54, PL63-PL68.	2.0	76
187	A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. <i>Journal of Physiology (Paris)</i> , 1993, 87, 313-327.	2.1	80
188	The effect of pentadecapeptide BPC 157 on inflammatory, non-inflammatory, direct and indirect pain and capsaicin neurotoxicity. <i>Inflammopharmacology</i> , 1993, 2, 121-127.	1.9	27
189	Hepatoprotective effect of BPC 157, A 15-aminoacid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin. <i>Life Sciences</i> , 1993, 53, PL291-PL296.	2.0	53
190	The significance of the gastroprotective effect of body protection compound (BPC): modulation by different procedures. <i>Acta Physiologica Hungarica</i> , 1992, 80, 89-98.	0.9	5
191	Dopamine agonists prevent duodenal ulcer relapse. <i>Digestive Diseases and Sciences</i> , 1991, 36, 905-910.	1.1	33
192	The influence of dopamine agonists and antagonists on indomethacin lesions in stomach and small intestine in rats. <i>European Journal of Pharmacology</i> , 1988, 158, 61-67.	1.7	34
193	The influence of dopamine agonists and antagonists on gastric lesions in mice. <i>European Journal of Pharmacology</i> , 1987, 144, 237-239.	1.7	12
194	Dopamine antagonists induce gastric lesions in rats. <i>European Journal of Pharmacology</i> , 1986, 131, 105-109.	1.7	37
195	The role of dopamine in the formation of gastric ulcers in rats. <i>European Journal of Pharmacology</i> , 1985, 112, 127-128.	1.7	32
196	The pentadecapeptide BPC 157 antagonizes the effect of atropine effect in the rats` eyes. <i>Acta Ophthalmologica</i> , 0, 85, 0-0.	0.4	0